We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
PURPOSE The phase III BEYOND trial was undertaken to confirm in a Chinese patient population the efficacy seen with first-line bevacizumab plus platinum doublet chemotherapy in globally conducted studies . PATIENTS AND METHODS Patients age ≥ 18 years with locally advanced , metastatic , or recurrent advanced nonsquamous non-small-cell lung cancer ( NSCLC ) were r and omly assigned to receive carboplatin ( area under the curve , 6 ) intravenously and paclitaxel ( 175 mg/m(2 ) ) intravenously ( CP ) on day 1 of each 3-week cycle , for ≤ six cycles , plus placebo ( Pl+CP ) or bevacizumab ( B+CP ) 15 mg/kg intravenously , on day 1 of each cycle , until progression , unacceptable toxicity , or death . The primary end point was progression-free survival ( PFS ) ; secondary end points were objective response rate , overall survival , exploratory biomarkers , safety . RESULTS A total of 276 patients were r and omly assigned , 138 to each arm . PFS was prolonged with B+CP versus Pl+CP ( median , 9.2 v 6.5 months , respectively ; hazard ratio [ HR ] , 0.40 ; 95 % CI , 0.29 to 0.54 ; P < .001 ) . Objective response rate was improved with B+CP compared with Pl+CP ( 54 % v 26 % , respectively ) . Overall survival was also prolonged with B+CP compared with Pl+CP ( median , 24.3 v 17.7 months , respectively ; HR , 0.68 ; 95 % CI , 0.50 to 0.93 ; P = .0154 ) . Median PFS was 12.4 months with B+CP and 7.9 months with Pl+CP ( HR , 0.27 ; 95 % CI , 0.12 to 0.63 ) in EGFR mutation-positive tumors and 8.3 and 5.6 months , respectively ( HR , 0.33 ; 95 % CI , 0.21 to 0.53 ) , in wild-type tumors . Safety was similar to previous studies of B+CP in NSCLC ; no new safety signals were observed . CONCLUSION The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and result ed in a clinical ly meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV